DENGUE FEVER

This study tests a dengue vaccine (TDV) in children aged 6 to 21 months. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive two shots three months apart and are monitored for side effects and antibody levels.

This phase 3 trial is testing a dengue vaccine (TDV) in 800 adults aged 45 to 79, including those with diabetes, high blood pressure, or kidney disease. Participants will receive two shots three months apart. The study aims to check for side effects and measure the immune respons…

This study looks at whether the dengue vaccine (TDV) helps prevent hospital stays due to dengue in children and teens in Thailand, Indonesia, and Malaysia. Researchers will follow 70,000 participants for 3 years, comparing those who got the vaccine with those who did not. The goa…

This study creates a registry to collect data on dengue infections in people with congenital bleeding disorders like hemophilia. Dengue can cause serious bleeding, and those with bleeding disorders may face higher risks. The goal is to understand bleeding complications, treatment…

This study follows 100 people with confirmed dengue to identify which symptoms and lab results predict hospitalization. It also tracks how often blood transfusions are given and their outcomes. The goal is to improve care for dengue patients, not to test a new treatment.